title: Moclobemide versus tranylcypromine in the treatment of depression.
abstract: Moclobemide and tranylcypromine were compared in 2 randomized groups of 20 depressed patients each. Fifteen of the patients on moclobemide and 18 of those on tranylcypromine were diagnosed as suffering from endogenous depression. The dosage was 150-300 mg moclobemide and 15-30 mg tranylcypromine daily. At the end of treatment, improvement on the Hamilton Rating Scale for Depression was 59.3% in the moclobemide group and 65.5% in the tranylcypromine group. The final overall assessment of efficacy was good or very good for 68% of the patients on moclobemide and for 85% of those on tranylcypromine. The final assessment of tolerance was good or very good for 85% of the moclobemide patients and 100% of the tranylcypromine patients. None of the differences in scores between the groups were statistically significant. This study therefore yielded comparable results for efficacy and tolerance of the 2 drugs in the treatment of depression.
authors: Hospital Psichiatrico, Santiago de Chile.
authors: L
authors: L
authors: Rossel
authors: E
authors: E
authors: Moll
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D014191:Tranylcypromine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000928:Antidepressive Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D014191:Tranylcypromine; D020912:Moclobemide